The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Abstract Aims Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. Methods and results The baseline 12-item Kansas City...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European heart journal 2021-08, Vol.42 (31), p.3011-3020
Hauptverfasser:	Jankowska, Ewa A, Kirwan, Bridget-Anne, Kosiborod, Mikhail, Butler, Javed, Anker, Stefan D, McDonagh, Theresa, Dorobantu, Maria, Drozdz, Jarosław, Filippatos, Gerasimos, Keren, Andre, Khintibidze, Irakli, Kragten, Hans, Martinez, Felipe A, Metra, Marco, Milicic, Davor, Nicolau, José C, Ohlsson, Marcus, Parkhomenko, Alexander, Pascual-Figal, Domingo A, Ruschitzka, Frank, Sim, David, Skouri, Hadi, van der Meer, Peter, Lewis, Basil S, Comin-Colet, Josep, von Haehling, Stephan, Cohen-Solal, Alain, Danchin, Nicolas, Doehner, Wolfram, Dargie, Henry J, Motro, Michael, Friede, Tim, Fabien, Vincent, Dorigotti, Fabio, Pocock, Stuart, Ponikowski, Piotr
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia, Iron-Deficiency - drug therapy Clinical Research Ferric Compounds - therapeutic use Heart Failure - complications Heart Failure - drug therapy Humans Iron - therapeutic use Maltose - therapeutic use Quality of Life Stroke Volume Treatment Outcome Ventricular Function, Left
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!